In Wednesday’s show, we look at a new cancer drug, Avastin, which can reportedly extend patients’ lives. So just how much medical care should be made available to patients at the end of their lives?
Henry Aaron, a senior fellow and noted health care expert with the Brookings Institution in Washington DC, joins Martin Savidge to discuss the issue.
To view this site, you need to have Flash Player 9
or later installed. Click here to get the latest Flash player.
Tell Us What You Think:
In an effort to bring down healthcare costs, should the U.S. government limit payment for cancer-fighting drugs that only extend life by a few months?
Please remember to be respectful and on-point in your comments. Malicious or offensive comments will be deleted and repeat offenders will be banned.
NOTE: Information you supply on this page will only be used to send this email. We request your name and email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. All fields marked with an asterisk (*) are required.